CENT vs CL: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of August 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

Reading it: CENT is the cheaper of the two on forward earnings, but cheaper is not the same as better. Pair the valuation with growth (how far the forward P/E sits below the trailing P/E) and risk (beta) before you decide.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. CENT and CL share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined CENT and CL exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

Central Garden & Pet sells the physical goods that keep a lawn alive and a pet fed. Two segments carry the whole company: Garden, which covers grass seed, wild bird feed, fertiliser, controls and pottery under names such as Pennington, Amdro and Sevin, and Pet, which spans aquatics, small animal and reptile supplies, dog and cat treats, flea and tick products and equine care under Kaytee, Aqueon, Farnam and Comfort Zone. Distribution runs mostly through big box retail, pet specialty chains, grocery and e-commerce, which is why the business is more sensitive to retailer inventory decisions and to a wet or dry spring than a typical packaged goods name. Fiscal 2025 net sales landed at ~$3.13B, and trailing twelve month sales sit at ~$3.08B after management deliberately exited a low margin pet distribution business.

Full CENT guide

Colgate-Palmolive is a global consumer-staples company that makes everyday household and personal-care products. It is a worldwide leader in oral care, where its Colgate-branded toothpaste, toothbrushes, and mouthwash hold a leading global share, and it also sells personal care (soaps, body wash, deodorants under brands like Palmolive, Softsoap, Irish Spring, and Sanex), home care (dish and surface cleaners such as Palmolive and Ajax), and pet nutrition through its Hill's Pet Nutrition business (Science Diet and Prescription Diet). Colgate makes money by selling these branded, frequently repurchased products at scale across more than 200 countries and territories, with a particularly large presence in emerging markets. Its competitive advantages come from powerful brands, vast distribution, and pricing power on staple goods. Headquartered in New York City, Colgate is a defensive, dividend-paying company whose products people buy regardless of the economic cycle.

Full CL guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• CENT drivers: The share class spread is the first variable, not a footnote; Central issues Class A, which quietly dilutes CENT's share of the equity.
• CL drivers: Oral-care leadership and emerging markets; Hill's Pet Nutrition growth.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: Governance is the structural risk specific to this ticker: a CENT holder owns one vote per share in a company where unlisted Class B holders may cast up to 49% of total votes, so minority influence over board composition or a change of control is limited by design. For CL, colgate's growth is structurally slow: it competes in mature, saturated staples categories where volume gains are hard to come by and much of recent revenue growth has come from price increases that may not persist.

Pick CENT if you believe its drivers more; CL if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the CENT and CL guides.

CENT. One set of earnings supports two different multiples here, because CENT at ~$43.82 and CENTA at ~$38.20 divide the same ~$2.67 of trailing EPS. Screeners commonly quote a ~$2.7B market cap for Central by applying CENT's price to all ~62.6 million shares across every class, whereas valuing each class at its own quoted price puts the figure nearer ~$2.5B, a gap worth knowing before comparing Central's enterprise value of ~$3.15B or its ~9.5x EV/EBITDA against single class peers. Beta of ~0.54 and a ~5.4% net margin describe a low volatility, thin margin consumer goods business rather than a growth story.

CL. Colgate trades at a premium consumer-staples multiple that reflects its defensive, recession-resistant cash flows, leading oral-care brands, the growth of Hill's, and a multi-decade dividend-raising record. The valuation premium is the market paying for stability and pricing power, balanced against the reality of slow underlying volume growth in mature categories.

Headline figures (approximate, August 2026): CENT shows revenue (ttm) ~$3.08B, net income (ttm) ~$166M, diluted eps (ttm) ~$2.67, p/e on cent vs centa ~16.4x vs ~14.3x; CL shows revenue (ttm) ~$20 billion, operating margin ~20-21%, net income (ttm) ~$2.7 billion, dividend yield ~2-2.5% (Dividend King).

CENT and CL are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined CENT and CL exposure against your real portfolio. It is not an investment adviser.